Added to YB: 2024-11-15
Pitch date: 2024-11-15
MREO [bullish]
Mereo BioPharma Group plc
-39.72%
current return
Author Info
Raging Bull Investments is a lawyer by background who shares actionable investment ideas on value opportunities with a catalyst. Sign up for the newsletter.
Company Info
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
Market Cap
$281.6M
Pitch Price
$3.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.22
P/E
-5.60
EV/Sales
452.15
Sector
Biotechnology
Category
special_situation
Actionable Ideas Update - 11/14/2024 - Mereo BioPharma Group plc
MREO: Alvelestat Phase 3 readiness by year-end requires partnership/financing. Recent AstraZeneca agreement amendment hints at potential deal. Setrusumab interim results offer upside without bad readout risk until mid-2025. Holding recommended, but reconsider if no alvelestat news by year-end.
Read full article (2 min)